The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.
Although (-)-deprenyl is known to be metabolized to methamphetamine and amphetamine, two small-scale double-blind trials indicate that neither metabolite contributes to all therapeutic benefit conferred by this drug in certain patients with Parkinson's disease: the manipulation of urinary pH, which alters the rate of excretion of these metabolites, failed to change the response pattern; substitution of a metabolite mixture for active drug caused a falling off in benefit.
D000661:Amphetamine / Q000627:therapeutic use* / Q000652:urine; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007980:Levodopa / Q000627:therapeutic use*; D008694:Methamphetamine / Q000627:therapeutic use* / Q000652:urine; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000652:urine; D010627:Phenethylamines / Q000627:therapeutic use*; D012642:Selegiline / Q000627:therapeutic use*
D010627:Phenethylamines; D012642:Selegiline; D008694:Methamphetamine; D007980:Levodopa; D000661:Amphetamine